Opinion: Reexamination of Failed DMD Trial a Much-Needed Reckoning for FibroGen
Biospace,
Pictured: Scientists analyze data on computers in a lab/iStock, gorodenkoff Despite finding initial success in Phase II…
Pictured: Scientists analyze data on computers in a lab/iStock, gorodenkoff Despite finding initial success in Phase II…
By David Bautz, PhD OTC:ICOTF | TSX:MSCL.V Satellos Bioscience Inc. (OTC:ICOTF)(TSX:MSCL.V) is a Canadian biotechnology company…
The Duchenne muscular dystrophy community's outrage over the $89,000 annual price tag announced for deflazacort (Emflaza)…
The annual $89,000 price-tag on an old corticosteroid, which was granted orphan drug status for treating Duchenne muscular…